About
Corona Remedies IPO is a book build issue of ₹655.37 crores. The issue is entirely an offer for sale of 0.62 crore shares of ₹655.37 crore.
Corona Remedies IPO bidding started from Dec 8, 2025 and ended on Dec 10, 2025. The allotment for Corona Remedies IPO was finalized on Dec 11, 2025. The shares got listed on BSE, NSE on Dec 15, 2025.
Corona Remedies IPO price band is set at ₹1,062 per share. The lot size for an application is 14. The minimum amount of investment required by an retail is ₹14,868 (14 shares) (based on upper price). The lot size investment for sNII is 14 lots (196 shares), amounting to ₹2,08,152, and for bNII, it is 68 lots (952 shares), amounting to ₹10,11,024.
The issue includes a reservation of up to 58,035 shares for employees offered at a discount of ₹54.00 to the issue price.
JM Financial Ltd. is the book running lead manager and Bigshare Services Pvt.Ltd. is the registrar of the issue.
Refer to Corona Remedies IPO RHP for detailed Information.
IPO Stock Quote & Charts
IPO Open
Mon, Dec 8, 2025
IPO Close
Wed, Dec 10, 2025
Issue Price
₹1062 per share
Market Cap (Pre-IPO)
₹6,495.20 Cr
IPO Details
| IPO Date | 8 to 10 Dec, 2025 |
| Listed on | Mon, Dec 15, 2025 |
| Face Value | ₹10 per share |
| Price Band | ₹1008 to ₹1062 |
| Issue Price | ₹1062 per share |
| Lot Size | 14 Shares |
| Sale Type | Offer For Sale |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Employee Discount | ₹54.00 |
| Total Issue Size | 61,74,051 shares (agg. up to ₹655 Cr) |
| Share Holding Pre Issue | 6,11,60,088 shares |
| Share Holding Post Issue | 6,11,60,088 shares |
| BSE Script Code / NSE Symbol | 544644 / CORONA |
| ISIN | INE02ZQ01018 |
IPO Timetable
- IPO OpenMon, Dec 8, 2025
- IPO CloseWed, Dec 10, 2025
- AllotmentThu, Dec 11, 2025
- RefundFri, Dec 12, 2025
- Credit of SharesFri, Dec 12, 2025
- ListingMon, Dec 15, 2025
IPO Reservation
Corona Remedies IPO offers total 61,74,051 shares. Out of which 30,58,007 (49.53%) allocated to QIB, 12,23,203 (19.81%) allocated to QIB (Ex- Anchor), 9,17,403 (14.86%) allocated to
NII
21,40,606 (34.67%) allocated to RII and 18,34,804 (29.72%) allocated to Anchor investors.
| Investor Category | Shares Offered | Max Allottees |
|---|---|---|
| QIB Shares Offered | 30,58,007 (49.53%) | NA |
| − Anchor Investor Shares Offered | 18,34,804 (29.72%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 12,23,203 (19.81%) | NA |
| NII (HNI) Shares Offered | 9,17,403 (14.86%) | NA |
| − bNII > ₹10L | 6,11,602 (9.91%) | 3,120 |
| − sNII < ₹10L | 3,05,801 (4.95%) | 1,560 |
| Retail Shares Offered | 21,40,606 (34.67%) | 1,52,900 |
| Employee Shares Offered | 58,035 (0.94%) | NA |
| Total Shares Offered | 61,74,051 (100.00%) |
IPO Lot Size
Investors can bid for a minimum of 14 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹14,868 |
| Retail (Max) | 13 | 182 | ₹1,93,284 |
| S-HNI (Min) | 14 | 196 | ₹2,08,152 |
S-HNI (Max) | 67 | 938 | ₹9,96,156 |
B-HNI (Min) | 68 | 952 | ₹10,11,024 |
IPO Anchor Investors
Corona Remedies IPO raises ₹194.86 crore from anchor investors. Corona Remedies IPO Anchor bid date is December 5, 2025.
📝 Anchor Investors Letter (PDF)
| Bid Date | Fri, Dec 5, 2025 |
| Shares Offered | 18,34,804 |
| Anchor Portion (₹ Cr.) | 194.86 |
| Anchor lock-in period end date for 50% shares (30 Days) | Fri, Jan 9, 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | Tue, Mar 10, 2026 |
Investor Category Reservations
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Up to Rs 5 Lakhs | Yes |
| Employee + RII/NII |
| Yes for Employee and RII/NII |
- Employee limit: Up to Rs 5 Lakhs (In certain cases, employees are given discount if bidding amount is upto Rs. 2 lakhs)
- If applying as RII: Upto Rs. 2 lakhs
- If applying as NII: sNII > Rs. 2 lakhs and upto Rs. 10 lakhs and bNII > Rs. 10 lakhs
About Corona Remedies Ltd.
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.
As of June 30, 2025, the company’s diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory).
The company has a pan-India marketing and distribution network with 2,671 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.
The company has two manufacturing facilities, located in the states of Gujarat with an aggregate installed capacity for formulations of 1,285.44 million units per
annum.
Competitive Strength:
- Second fastest growing company in the top 30 Indian pharmaceutical companies by domestic sales from MAT June 2022 to MAT June 2025, well-positioned to seize opportunities in the Indian market.
- Demonstrated capabilities of building a diversified portfolio, including “engine” brands, in our targeted therapy areas.
- Pan-India sales network and marketing strategy focused on the “middle of the pyramid” target market.
- Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities driving a portfolio of differentiated pharmaceutical products.
- Qualified, experienced and entrepreneurial management team supported by marquee investors.
Company Financials (Restated Consolidated)
Corona Remedies Ltd.’s revenue increased by 18% and profit after tax (PAT) rose by 65% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,012.38 | 929.86 | 830.58 | 595.02 |
| Total Income | 348.56 | 1,202.35 | 1,020.93 | 891.10 |
| Profit After Tax | 46.20 | 149.43 | 90.50 | 84.93 |
| EBITDA | 71.80 | 245.91 | 161.19 | 135.03 |
| NET Worth | 607.02 | 606.34 | 480.41 | 408.52 |
| Reserves and Surplus | 545.86 | 545.18 | 419.25 | 347.36 |
| Total Borrowing | 106.65 | 62.70 | 134.14 | 2.33 |
| Amount in ₹ Crore | ||||
Key Performance Indicator (KPI)
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 27.50% |
| ROCE | 41.32% |
| Debt/Equity | 0.10 |
| RoNW | 24.65% |
| PAT Margin | 12.49% |
| EBITDA Margin | 20.55% |
| Price to Book Value | 10.71 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 24.43 | 30.21 |
| P/E (x) | 43.47 | 35.15 |
| Promoter Holding | 72.50% | 69% |
| Market Cap | ₹6,495.20 Cr. |
- The value will be calculated using Equity Dilution = Share Holding Pre Issue – Share Holding Post Issue
- The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2025 available in RHP.
- The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of June 30, 2025 available in RHP.
IPO Review
Corona Remedies IPO Recommendations
| Review By | Subscribe | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Brokers | 13 | 1 | 0 | 0 |
| Members | 0 | 0 | 0 | 0 |
Corona Remedies IPO Subscription Status (Bidding Detail)
The Corona Remedies IPO is subscribed 144.54 times on December 10, 2025 6:19:37 PM (Day 3). The public issue subscribed 30.39 times in the retail category, 293.80 times in the QIB category, and 220.18 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category |
Subscription (times) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB (Ex Anchor) | 293.80 | 12,21,729 | 35,89,39,448 |
| NII | 220.18 | 9,16,960 | 20,18,97,066 |
| bNII (bids above ₹10L) | 246.67 | 6,11,307 | 15,07,93,356 |
| sNII (bids below ₹10L) | 167.20 | 3,05,653 | 5,11,03,710 |
| Retail | 30.39 | 21,39,573 | 6,50,20,704 |
| Employee | 15.56 | 58,036 | 9,02,888 |
| Total | 144.54 | 43,36,298 | 62,67,60,106 |
Total Application : 41,87,186
IPO Expenses
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | BRLMs fees and commissions (including underwriting commission, brokerage and selling commission) | 21.03 |
| 2 | Fees payable to the Registrar to the Offer | 0.50 |
| 3 | Selling commission/processing fee for SCSBs and Bankers to the Offer, fee payable to the Sponsor Bank(s) for Bids made by RIIs using UPI, brokerage and selling commission and bidding charges for the Members of the Syndicate, Registered Brokers, RTAs and CDPs | 3.07 |
| 4 | Advertising and marketing expenses | 2.41 |
| 5 | Others | |
| 6 | Listing fees, SEBI filing fees, upload fees, BSE and NSE processing fees, book building software fees | 7.11 |
| 7 | Other regulatory expenses | |
| 8 | Printing and stationery expenses | 1.17 |
| 9 | Fees payable to legal counsels | 8.81 |
| 10 | Fees payable to other advisors to the Offer, including but not limited to Statutory Auditors, independent chartered accountant, practising company secretary, industry expert | 4.01 |
| 11 | Miscellaneous | 3.85 |
Listing Day Trading Information
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹1,062.00 | ₹1,062.00 |
| Open | ₹1,452.00 | ₹1,470.00 |
| Low | ₹1,412.65 | ₹1,413.00 |
| High | ₹1,499.00 | ₹1,497.80 |
| Last Trade | ₹1,437.20 | ₹1,438.40 |
Check IPO Performance…
IPO Registrar
Bigshare Services Pvt.Ltd.
- +91-22-6263 8200
- ipo@bigshareonline.com
- Visit Website
IPO Lead Manager(s)
- JM Financial Ltd. (Past IPO Performance)
- IIFL Capital Services Ltd. (Past IPO Performance)
- Kotak Mahindra Capital Co.Ltd. (Past IPO Performance)
Lead Manager Reports
- Lead Manager Performance Summary
- Lead Manager Performance Tracker
Contact Details
- +91 79 4023 3000
- complianceofficer@coronaremedies.com
- Visit Website
IPO FAQs
What is the Corona Remedies IPO?
Corona Remedies IPO is a main-board IPO of 61,74,051 equity shares of the face value of ₹10 aggregating up to ₹655 Crores. The issue is priced at ₹1062 per share. The minimum order quantity is 14.
The IPO opens on Mon, Dec 8, 2025, and closes on Wed, Dec 10, 2025.
Bigshare Services Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
How to apply in Corona Remedies IPO through Zerodha?
Zerodha customers can apply online in Corona Remedies IPO using UPI as a payment gateway. Zerodha customers can apply in Corona Remedies IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Corona Remedies IPO through Zerodha
- Visit the Zerodha website and login to Console.
- Go to Portfolio and click the IPOs link.
- Go to the ‘Corona Remedies IPO‘ row and click the ‘Bid’ button.
- Enter your UPI ID, Quantity, and Price.
- Submit IPO application form.
- Visit the UPI App (net banking or BHIM) to approve the mandate.
Visit Zerodha IPO Application Process Review for more detail.
When Corona Remedies IPO will open?
The Corona Remedies IPO opens on Mon, Dec 8, 2025 and closes on Wed, Dec 10, 2025.
What is the lot size of Corona Remedies IPO?
Corona Remedies IPO lot size is 14, and the minimum amount required for application is ₹14,868.
How to apply for Corona Remedies IPO?
You can apply in Corona Remedies IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don’t offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
When is Corona Remedies IPO allotment?
The finalization of Basis of Allotment for Corona Remedies IPO will be done on Thursday, December 11, 2025, and the allotted shares will be credited to your demat account by Fri, Dec 12, 2025. Check the Corona Remedies IPO allotment status.
When is Corona Remedies IPO listing date ?
The Corona Remedies IPO listing date is on Mon, Dec 15, 2025.
About The Author
